Among the most controversial decisions of this cycling season is the Vuelta a España’s choice to exclude Equipo Kern Pharma from the wildcard entries—handing that coveted spot instead to Q36.5 Pro Cycling Team. It’s a move that raises fundamental questions about meritocracy and strategic foresight in Grand Tour invitations.
Let’s be clear: wildcard selections shouldn’t be handed out like commemorative bidons. While national representation alone doesn’t justify an invitation, Equipo Kern Pharma had a compelling case. Consistent performances, a clear developmental strategy, and a growing fan base all made them deserving candidates. The fact that they’ve been overlooked in favour of Q36.5, a team only recently thrust into the limelight by the high-profile signing of Tom Pidcock, is difficult to rationalise.
Pidcock’s presence undoubtedly brings attention, but should star power outweigh sporting merit? His recent Giro d’Italia performance doesn’t support the hype. Despite flashes of form—third in Matera (Stage 5), fourth in Castelnovo ne’ Monti (Stage 11), and fifth in Tirana (Stage 1)—he largely failed to animate the race. Finishing 16th overall, 44 minutes adrift of Simon Yates, Pidcock’s Giro was more background noise than headline act.
It’s not the first time Pidcock’s calendar has seemed overambitious. His past two Tour de France outings with INEOS offered similar stories: talent spread thin across disciplines, leaving few results to show at the highest level. The Giro’s terrain and tempo appeared well-suited for a rider of his explosive profile, yet the impact was minimal—made even more striking by the relatively average GC field this year.
In contrast, Equipo Kern Pharma has been building something real. Their 2024 season has showcased tactical discipline, rider development, and an attacking spirit emblematic of what wildcard slots should reward. To see them sidelined, especially in a Spanish Grand Tour, is a gut-punch—not just for the team, but for fans who appreciate progression built on performance rather than reputation.
Maybe Pidcock will light up the Vuelta if he lines up. But basing a wildcard allocation on potential celebrity impact over proven consistency is a gamble that dilutes the very essence of competitive sport. Kern Pharma’s omission isn’t just disappointing—it’s unjust.